# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Flannery O'Connor (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML046-SYN-TD
- Date: 1950-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Augusta Pemberton-Diallo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review of lupus nephritis; pregnancy planning. **S**

## History of present illness

Ms. O'Connor is six months into treatment. She reached prednisone 5 mg a day a week ago. Her joints and skin remain quiet; she has had no fevers, infections, or hip pain since the summer. Monthly blood counts have been normal. She had her influenza vaccine at the preventive visit three weeks ago. She has finished a draft of her novel. She would like to have children in a few years and asked what that would mean for her treatment. **S**

| Element | Detail |
|---|---|
| Interval change | Prednisone 5 mg a day; no flares or infections |
| Medicines | Mycophenolate 2 g a day; belimumab weekly; hydroxychloroquine 300 mg; losartan 25 mg; vitamin D3 |
| Question | Pregnancy in a few years |
| Work | Draft of her novel finished |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight falling |
| Musculoskeletal | Negative | No joint pain; no hip, groin, or knee pain |
| Integumentary | Negative | No rash; hair regrowing |
| Genitourinary | Negative | No urinary symptoms |
| Psychiatric | Negative | Mood good; PHQ-9 3 |

5 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day **S**
- Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term **S**
- Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure **S**
- Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months **S**
- Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily **S**
- Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 62 kg; BMI 22 kg/m². All vital signs are synthetic.

Hemoglobin: 12.8 g/dL; White cell count: 5.6 10*3/uL; Lymphocytes: 1.2 10*3/uL; Platelets: 236 10*3/uL; Creatinine: 0.8 mg/dL; eGFR: 101 mL/min/1.73 m²; Potassium: 4.3 mmol/L; Albumin: 4.1 g/dL; ALT: 20 U/L; Urine protein-to-creatinine ratio: 0.35 g/g (high); Urine red cells: 2 /[HPF]; Anti-dsDNA: 38 [IU]/mL (high); Complement C3: 96 mg/dL; Complement C4: 18 mg/dL; PHQ-9: 3; Joint pain (0 to 10): 0. All results are synthetic.

## Change since baseline

- Hemoglobin: 11 g/dL (low) at baseline, 12.8 g/dL at this visit **S**
- White cell count: 3.3 10*3/uL (low) at baseline, 5.6 10*3/uL at this visit **S**
- Lymphocytes: 0.8 10*3/uL (low) at baseline, 1.2 10*3/uL at this visit **S**
- Platelets: 138 10*3/uL (low) at baseline, 236 10*3/uL at this visit **S**
- Creatinine: 0.8 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR: 101 mL/min/1.73 m² at baseline, 101 mL/min/1.73 m² at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Albumin: 3.3 g/dL (low) at baseline, 4.1 g/dL at this visit **S**
- ALT: 19 U/L at baseline, 20 U/L at this visit **S**
- Urine protein-to-creatinine ratio: 1.6 g/g (high) at baseline, 0.35 g/g (high) at this visit **S**
- Urine red cells: 18 /[HPF] (high) at baseline, 2 /[HPF] at this visit **S**
- PHQ-9: 7 at baseline, 3 at this visit **S**
- Joint pain (0 to 10): 6 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Skin | No rash; no mouth ulcers |
| Musculoskeletal | No synovitis; full, painless hip movement |
| Cardiovascular | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Class III lupus nephritis** (M32.14). Complete renal response at six months: protein-to-creatinine ratio 0.35 g/g, red cells 2 per high-power field, creatinine 0.8. Anti-dsDNA 38 and complements normal (C3 96, C4 18). Treatment continues for three to five years after a complete response before any reduction. **S**
   - Continue mycophenolate, belimumab, hydroxychloroquine, and losartan.
   - Prednisone 5 mg; withdrawal to be considered after a further period of quiet disease.
   - Kidney panel, urine protein, and serology every three months.
2. **Pregnancy planning** (Z97.5). Pregnancy is possible and safest after at least six months of quiet disease on pregnancy-compatible medicines. Her negative antiphospholipid tests mean no heparin is expected. Lupus nephritis raises the risk of preeclampsia. **S**
   - When she is ready: switch mycophenolate to azathioprine and stop losartan, with at least six weeks off mycophenolate before trying and a period of stability on azathioprine first.
   - Continue hydroxychloroquine through pregnancy; belimumab reviewed with her rheumatologist before conception.
   - Anti-Ro and anti-La antibodies before pregnancy; low-dose aspirin from 12 weeks; joint care with obstetrics.
   - Keep the intrauterine system until then.
3. **Glucocorticoids: bone** (Z79.52). No hip pain; vitamin D replete. **S**
   - Repeat DXA in one to two years while on glucocorticoids.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Urine protein-to-creatinine ratio and urine sediment | Every 3 months during active treatment | Completed today | 0.35 g/g; 2 red cells per high-power field: complete renal response |
| Laboratory | Creatinine, eGFR, albumin, and potassium | Every 3 months during active treatment | Completed today | Creatinine 0.8, eGFR 101, albumin 4.1, potassium 4.3 |
| Laboratory | Anti-dsDNA, C3, and C4 | Every 3 months during active treatment | Completed today | Anti-dsDNA 38; C3 96; C4 18 |
| Laboratory | Blood count and liver tests on mycophenolate | Monthly in the first year | Completed today | White cells 5.6, lymphocytes 1.2, hemoglobin 12.8, platelets 236; ALT 20 |
| Examination | Blood pressure | Every visit | Completed today | 118/76 mmHg |
| Medication safety | Glucocorticoid dose | Every visit | Completed today | Prednisone 5 mg a day at six months, as planned |
| Examination | Avascular necrosis symptoms | Every visit | Completed today | No hip, groin, or knee pain |
| Imaging | Bone density (DXA) | Every 1 to 3 years on glucocorticoids | Up to date | Normal six months ago |
| Medication safety | Hydroxychloroquine eye screening | Yearly from five years of use | Up to date | Baseline normal four months ago |
| Medication safety | Vaccinations | Yearly influenza; others as due | Up to date | Influenza three weeks ago; PCV20 and two zoster doses done; COVID-19 booked |
| Medication safety | Contraception and pregnancy planning | Every visit | Completed today | Intrauterine system in place; pregnancy plan discussed |
| Laboratory | Anti-Ro and anti-La antibodies | Before pregnancy | Due | When she plans a pregnancy |
| Laboratory | Lipids | Yearly on glucocorticoids | Due | At one year |
| Survey | Mood on belimumab (PHQ-9) | Periodically | Completed today | PHQ-9 3 |
| Survey | Joint pain score | Every visit | Completed today | 0 of 10 |
| Self-management | Sun protection and writing schedule | Every visit | Completed today | Sunscreen daily; draft of her novel finished |

## Goal progress

- Establish the diagnosis within two weeks and hear it directly, in plain words. Outcome by 1950-04-22: Told directly at nine days that she has systemic lupus erythematosus, with the reasons and a written summary. **S**
- Renal response: urine protein-to-creatinine ratio halved by three months and below 0.5 g/g with stable kidney function by six to twelve months. Outcome by 1950-10-26: Ratio 1.8 at diagnosis, 0.9 at three months, 0.35 at six months, a complete response; creatinine 0.8 throughout. **S**
- Prednisone 5 mg a day or less by six months, with withdrawal considered later. Outcome by 1950-10-26: 5 mg a day at six months. **S**
- Write at least four mornings a week through treatment. In progress; target 1950-12-31. **S**
- No unplanned pregnancy on mycophenolate; plan any pregnancy for a time of quiet disease on compatible medicines. In progress; target 1950-12-31. **S**

## Guideline basis

- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023), EULAR
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024), American College of Rheumatology
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 2020;72(4):461-488 (2020), American College of Rheumatology
- CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026), U.S. National Library of Medicine, DailyMed
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease and hypertension monographs (2026), Aether Forge

## Follow-up

- Rheumatology every three months with kidney panel, urine protein, and serology. Blood counts monthly to one year. Primary care review in three months. **S**

